A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer

NCT01711970 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum Resistant Ovarian Cancer

Interventions

DRUG: Paclitaxel

Sponsor

Vascular Biogenics Ltd. operating as VBL Therapeutics